Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis - PubMed
7 hours ago
- #Cholestasis Treatment
- #Primary Biliary Cholangitis
- #Peroxisome Proliferator-Activated Receptors
- PPAR agonists serve as second-line therapy for primary biliary cholangitis (PBC) when first-line UDCA is insufficient or not tolerated.
- PPAR-α and PPAR-δ agonists help reduce cholestasis by lowering bile acid synthesis and inflammation, with PPAR-α also aiding in bile acid detoxification and transport.
- Pruritus improvement varies among PPAR agonists: PPAR-α predominant agents may have anti-pruritic effects, while selective PPAR-δ agonists like seladelpar show significant pruritus relief.
- Different PPAR isoforms are linked to distinct safety profiles, such as PPAR-α agonism with hepatic/muscle signals and PPAR-γ with fluid retention/weight gain.
- Future research should focus on isoform-specific mechanisms for symptom relief and managing agent- and class-related toxicities in PBC treatment.